Atara Biotherapeutics, Inc. (ATRA) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

High Risk
Significant dilution risk
Last updated: March 17, 2026

Risk Assessment Details

Potential Dilution: 2130.22% of current shares
Recent Dilution: 54.55% (2 years)
Historical Dilution Factor: significant recent dilution
Outstanding Shares
8.2M
Potential Supply
170M
Additional shares possible
Splits
None
Past 2 years

Summary

ATRA currently has 8.18M outstanding shares. with significant dilution risk as 174M authorized shares could dilute existing holders by 2130.2%. The company has significantly diluted shareholders by 54.55% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
Mar 17, 2026

S-3 filing: This prospectus relates to the resale, from time to time by HCR Molag Fund, L.P., the selling stockholder named in this prospectus, which we refer to as HCR or the selling stockholder, of up to 400,000 shares of our common stock, or the Shares, issuable upon the exercise of a warrant held by the selling stockholder, or the Warrant.

8.2M 170M
Mar 16, 2026

10-K filing | 8.2M shares outstanding

8.2M 170M
Nov 12, 2025

10-Q filing | 7.2M shares outstanding

7.2M 170M
Aug 11, 2025

10-Q filing | 7.0M shares outstanding

7M 170M
May 15, 2025

10-Q filing | 6.0M shares outstanding

6M 180M
Mar 07, 2025

10-K filing | 5.9M shares outstanding

5.9M 180M
Nov 12, 2024

10-Q filing | 5.8M shares outstanding

5.8M 180M
Aug 12, 2024

10-Q filing | 4.9M shares outstanding

4.9M 180M
May 09, 2024

10-Q filing | 120.4M shares outstanding

120M 62M
Mar 28, 2024

10-K filing | 119.4M shares outstanding

120M 63M
Nov 01, 2023

10-Q filing | 106.4M shares outstanding

110M 76M
Nov 01, 2023

S-3 filing: The company may offer and sell up to $400,000,000 of any combination of common stock, preferred stock, debt securities, and rights to purchase common stock, preferred stock, debt securities or units. Additionally, the company will offer common stock at-the-market through Cowen and Company, LLC, or TD Cowen, for up to $100,000,000.

110M 77M
Aug 08, 2023

10-Q filing | 105.1M shares outstanding

110M 0
May 08, 2023

10-Q filing | 104.0M shares outstanding

100M 0
Feb 09, 2023

POS AM filing: The company is filing a POS AM to offer and sell up to $375,000,000 of common stock, preferred stock, and debt securities, either individually or in combination with other securities.

100M 0
Feb 08, 2023

10-K filing | 102.0M shares outstanding

100M 0
Nov 08, 2022

10-Q filing | 102.4M shares outstanding

100M 0
Aug 08, 2022

10-Q filing | 101.6M shares outstanding

100M 0
May 05, 2022

10-Q filing | 93.4M shares outstanding

93M 0
Feb 28, 2022

10-K filing | 93.1M shares outstanding

93M 0
Nov 04, 2021

10-Q filing | 88.4M shares outstanding

88M 0
Aug 09, 2021

10-Q filing | 84.8M shares outstanding

85M 0
May 04, 2021

10-Q filing | 84.1M shares outstanding

84M 0
Mar 01, 2021

10-K filing | 83.6M shares outstanding

84M 0
Nov 09, 2020

10-Q filing | 77.7M shares outstanding

78M 0
Aug 05, 2020

10-Q filing | 74.3M shares outstanding

74M 0
May 06, 2020

10-Q filing | 59.0M shares outstanding

59M 0
Feb 27, 2020

10-K filing | 58.6M shares outstanding

59M 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime